In a cell-based screen of more than 650 Food and Drug Administration-approved compounds , we identified multiple members of the 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitor drug class ( referred to as statins ) that suppressed angiopoietin-2 .